Investors

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing products which reduce hunger and food cravings, enhance the gut microbiome, and sweet fibres as healthy sugar substitutes announces that its shares ("Ordinary Shares") have been approved to trade on the OTCQB Venture Market ("OTCQB") in the United States and will commence trading on the stock market at open on Thursday 21 August 2025 under the symbol "OPTBF".

Trading on the OTCQB market will not impact on existing ordinary shares admitted to trading on the AIM Market of the London Stock Exchange and no new ordinary shares were issued through this process. The Company will continue to make all announcements and disclosures to the London Stock Exchange through the Regulatory News Service and is not subject to any Sarbanes-Oxley or US Securities and Exchange Commission reporting requirements.

OTCQB is provided through OTC Markets Group Inc. (“OTC Markets”), located in New York. OTC Markets operates the world's largest electronic interdealer quotation system for US broker dealers and offers multiple media channels to increase the visibility of OTC-listed companies. OTCQB is a well-established market designed to provide enhanced visibility and liquidity for international companies seeking to broaden their U.S. investor base. Independent studies show that trading on the OTC by an international company offers a positive effect on the liquidity of its shares.

Stephen O’Hara CEO, commented: "OptiBiotix is building its consumer presence in the USA as shown by the recent launch of its appetite reducing SlimBiome® in Hydroxycut, the No. 1 selling weight loss supplement brand in the USA. This follows on from launches earlier this year with new US partners such as NHT and Daily Nouri. As we increase our brand presence in the USA the Board believe joining the OTCQB Market will help increase our visibility to the US investment community, broadening our shareholder base and improving liquidity."

 

The Directors of the Company are responsible for the release of this announcement.

For further information, please contact:   OptiBiotix Health plc		www.optibiotix.com
Neil Davidson, Chairman	Contact via Walbrook below
Stephen O'Hara, Chief Executive
Cairn Financial Advisers LLP (NOMAD and Broker)		Tel: 020 7213 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti
Walbrook PR Ltd		Mob: 07876 741 001
Anna Dunphy

 

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.